Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

This time may be different

The markets may be softening on biotech, but overall the sector remains in an incredibly strong environment.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Biotech's five-year bull market.
Figure 2: Biotech's current performance in context of long-term investment cycles.
Figure 3: This time is different.
Figure 4: Three things that are not different in biotech today.

References

  1. Ernst & Young. Biotech '92: Promise to Reality. Ernst & Young Annual Biotech Report. 1992 (Ernst & Young, New York, 1992).

  2. Slud, M. Boom time for biotech. CNNMoney (22 February 2000). http://money.cnn.com/2000/02/22/companies/biotech/

    Google Scholar 

  3. Thomas, D. & Wessel, C. Emerging therapeutic company investment and deal trends (Biotechnology Industry Organization, 11 June 2015). https://www.bio.org/sites/default/files/BIO%20Emerging%20Therapeutic%20Company%20Report%20June%2011%202015.pdf

  4. Ernst & Young. Beyond Borders: Reaching New Heights. Ernst & Young Annual Biotech Report 2015 (Ernst & Young, New York, 2015). http://www.ey.com/Publication/vwLUAssets/EY-beyond-borders-2015/$FILE/EY-beyond-borders-2015.pdf

  5. Schulze, U. et al. Nat. Rev. Drug Discov. 13, 331–332 (2014).

    CAS  Article  Google Scholar 

  6. Smietana, K. et al. Nat. Rev. Drug Discov. 14, 455–456 (2015).

    CAS  Article  Google Scholar 

  7. Booth, B. et al. Improving the Pharma Research Pipeline McKinsey Quarterly, Web Exclusive August 2004 (Mckinsey, New York, 2004)

    Google Scholar 

Download references

Acknowledgements

The author would like to thank his colleagues at Atlas Venture for their helpful perspectives and input into the sector, and both K. Margeson and E. Silva for data and graphical support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bruce L Booth.

Ethics declarations

Competing interests

B.L.B. participates in partnerships that invest in biotech venture capital and has a pecuniary financial interest in the success of those investments.

Source data

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Booth, B. This time may be different. Nat Biotechnol 34, 25–30 (2016). https://doi.org/10.1038/nbt.3452

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3452

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing